Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Peter Hartung

Showing results (141-150 of 601) with videos related to

Pageof 61
Sort By:
Neuropsychiatric Disease and Treatment|September 21, 2011
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosisClemens Warnke, Olaf Stüve, Hans-Peter Hartung, et al.
Current Opinion in Neurology|April 13, 2011
Risks and benefits of multiple sclerosis therapies: need for continual assessment?Bernd C Kieseier, Heinz Wiendl, Hans-Peter Hartung, et al.
CNS Drugs|July 11, 2019
Drug Treatment of Clinically Isolated SyndromeMoritz Förster, Jonas Graf, Jan Mares, et al.
Current Opinion in Neurology|April 29, 2026
Investigational approaches to multiple sclerosis therapyJoshua M Boeckers, Marc Pawlitzki, Hans-Peter Hartung, et al.
Journal of Neurology|October 18, 2023
Multiple sclerosis: time for early treatment with high-efficacy drugsKrzysztof Selmaj, Bruce A C Cree, Michael Barnett, et al.
Brain : a Journal of Neurology|May 7, 2004
In vivo MRI of brain inflammation in human ischaemic strokeAndreas Saleh, Michael Schroeter, Cornelia Jonkmanns, et al.
Expert Opinion on Pharmacotherapy|December 22, 2012
Cladribine tablets for the treatment of relapsing-remitting multiple sclerosisGiancarlo Comi, Hans-Peter Hartung, Nuwan C Kurukulasuriya, et al.
Deutsches Arzteblatt International|January 29, 2017
Interdisciplinary Risk Management in the Treatment of Multiple SclerosisJoachim Havla, Clemens Warnke, Tobias Derfuss, et al.
Journal of Neurology|August 2, 2024
MS treatment de-escalation: review and commentaryKrzysztof Selmaj, Hans-Peter Hartung, Marcin P Mycko, et al.
Plos One|January 13, 2017
Outcome and Treatment Effects in Stroke Associated with Acute Cervical ICA OcclusionMichael Gliem, John-Ih Lee, Aurica Barckhan, et al.
Pageof 61

Showing results (141-150 of 601) with videos related to

Sort By:
Pageof 61
Neuropsychiatric Disease and Treatment|September 21, 2011
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosisClemens Warnke, Olaf Stüve, Hans-Peter Hartung, et al.
Current Opinion in Neurology|April 13, 2011
Risks and benefits of multiple sclerosis therapies: need for continual assessment?Bernd C Kieseier, Heinz Wiendl, Hans-Peter Hartung, et al.
CNS Drugs|July 11, 2019
Drug Treatment of Clinically Isolated SyndromeMoritz Förster, Jonas Graf, Jan Mares, et al.
Current Opinion in Neurology|April 29, 2026
Investigational approaches to multiple sclerosis therapyJoshua M Boeckers, Marc Pawlitzki, Hans-Peter Hartung, et al.
Journal of Neurology|October 18, 2023
Multiple sclerosis: time for early treatment with high-efficacy drugsKrzysztof Selmaj, Bruce A C Cree, Michael Barnett, et al.
Brain : a Journal of Neurology|May 7, 2004
In vivo MRI of brain inflammation in human ischaemic strokeAndreas Saleh, Michael Schroeter, Cornelia Jonkmanns, et al.
Expert Opinion on Pharmacotherapy|December 22, 2012
Cladribine tablets for the treatment of relapsing-remitting multiple sclerosisGiancarlo Comi, Hans-Peter Hartung, Nuwan C Kurukulasuriya, et al.
Deutsches Arzteblatt International|January 29, 2017
Interdisciplinary Risk Management in the Treatment of Multiple SclerosisJoachim Havla, Clemens Warnke, Tobias Derfuss, et al.
Journal of Neurology|August 2, 2024
MS treatment de-escalation: review and commentaryKrzysztof Selmaj, Hans-Peter Hartung, Marcin P Mycko, et al.
Plos One|January 13, 2017
Outcome and Treatment Effects in Stroke Associated with Acute Cervical ICA OcclusionMichael Gliem, John-Ih Lee, Aurica Barckhan, et al.
Pageof 61